Tevogen Signs Letter of Intent to Evaluate HRK Healthcare Deal
The deal, which is non-binding, could help the Nasdaq-listed healthcare company build toward $100 million in combined annual revenue.
By Bootstrapped Wealth Money Desk
· 1 min read
Tevogen Inc., a Nasdaq-listed healthcare company based in Warren, New Jersey, said on October 8, 2026, that it had signed a non-exclusive, non-binding letter of intent to evaluate a possible acquisition of HRK Healthcare LLC, according to GlobeNewswire.
The letter of intent is non-binding, and the proposed transaction remains subject to due diligence, negotiation of definitive documentation, required approvals and other customary closing conditions.
Tevogen combines a biopharmaceutical arm, Tevogen Bio; a technology arm, Tevogen.AI; and an emerging healthcare services arm. Manmohan Patel, Tevogen's lead investor, said a completed HRK transaction, together with other acquisitions the company is considering, could help Tevogen reach approximately $100 million in combined annual revenue.
Ryan Saadi, Tevogen's chief executive, said the company is "hopeful that the proposed transaction could close by the end of the fourth quarter of 2026," but cautioned that there is no assurance on the timing or completion of the deal.
This story was first reported by GlobeNewswire (Small Business News).
Comments